BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner MA. Neonatal drug development. Early Hum Dev. 2011;87:763-768. [PMID: 21925812 DOI: 10.1016/j.earlhumdev.2011.08.014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Turner MA, Davis JM, McCune S, Bax R, Portman RJ, Hudson LD. The International Neonatal Consortium: collaborating to advance regulatory science for neonates. Pediatr Res 2016;80:462-4. [PMID: 27384407 DOI: 10.1038/pr.2016.119] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
2 Allegaert K. Better medicines for neonates: Improving medicine development, testing, and prescribing. Early Hum Dev 2017;114:22-5. [PMID: 28899617 DOI: 10.1016/j.earlhumdev.2017.09.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Bajčetić M, Spasić S, Spasojević I. Redox therapy in neonatal sepsis: reasons, targets, strategy, and agents. Shock 2014;42:179-84. [PMID: 24827393 DOI: 10.1097/SHK.0000000000000198] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
4 Nellis G, Metsvaht T, Varendi H, Lass J, Duncan J, Nunn AJ, Turner MA, Lutsar I. Product Substitution as a Way Forward in Avoiding Potentially Harmful Excipients in Neonates. Paediatr Drugs 2016;18:221-30. [PMID: 27099961 DOI: 10.1007/s40272-016-0173-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
5 Smith AM, Davis JM. Challenges and opportunities to enhance global drug development in neonates. Curr Opin Pediatr 2017;29:149-52. [PMID: 28092280 DOI: 10.1097/MOP.0000000000000463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
6 Belén Rivas A, Arruza L, Pacheco E, Portoles A, Diz J, Vargas E. Adverse drug reactions in neonates: a prospective study. Arch Dis Child 2016;101:371-6. [DOI: 10.1136/archdischild-2015-309396] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
7 Coppini R, Simons SHP, Mugelli A, Allegaert K. Clinical research in neonates and infants: Challenges and perspectives. Pharmacol Res 2016;108:80-7. [PMID: 27142783 DOI: 10.1016/j.phrs.2016.04.025] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
8 Allegaert K, Smits A, van den Anker JN. Drug evaluation studies in neonates: how to overcome the current limitations. Expert Rev Clin Pharmacol 2018;11:387-96. [PMID: 29421929 DOI: 10.1080/17512433.2018.1439378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
9 Dixon BJ, Reis C, Ho WM, Tang J, Zhang JH. Neuroprotective Strategies after Neonatal Hypoxic Ischemic Encephalopathy. Int J Mol Sci 2015;16:22368-401. [PMID: 26389893 DOI: 10.3390/ijms160922368] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 14.2] [Reference Citation Analysis]
10 Allegaert K. Clinical pharmacological studies in children: From exploratory towards confirmation driven methodology. World J Clin Pediatr. 2012;1:3-7. [PMID: 25254160 DOI: 10.5409/wjcp.v1.i2.3] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Samardzic J, Turner MA, Bax R, Allegaert K. Neonatal medicines research: challenges and opportunities. Expert Opin Drug Metab Toxicol 2015;11:1041-52. [PMID: 25958820 DOI: 10.1517/17425255.2015.1046433] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
12 Allegaert K, Simons S, Van Den Anker J. Research on medication use in the neonatal intensive care unit. Expert Rev Clin Pharmacol 2019;12:343-53. [PMID: 30741041 DOI: 10.1080/17512433.2019.1580569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Allegaert K, Langhendries JP, van den Anker JN. Educational paper: Do we need neonatal clinical pharmacologists. Eur J Pediatr. 2012;Epub ahead of print. [PMID: 22588521 DOI: 10.1007/s00431-012-1734-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
14 Valeur KS, Holst H, Allegaert K. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered. Pharmaceut Med 2018;32:251-8. [PMID: 30174435 DOI: 10.1007/s40290-018-0243-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
15 Kurul S, Allegaert K, Flint RB, Taal HR. "How can a drug to treat claudication in adults save preterm newborns?". Eur J Pediatr 2020;179:1331-4. [PMID: 32179979 DOI: 10.1007/s00431-020-03631-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Allegaert K. Tailored tools to improve pharmacotherapy in infants. Expert Opin Drug Metab Toxicol 2014;10:1069-78. [PMID: 24961300 DOI: 10.1517/17425255.2014.931937] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
17 Allegaert K. Neonates need tailored drug formulations. World J Clin Pediatr 2013;2:1-5. [PMID: 25254168 DOI: 10.5409/wjcp.v2.i1.1] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Viscardi RM. Pharmacological options for BPD prevention: steps for better clinical trial design. J Perinatol 2014;34:656-7. [PMID: 25179379 DOI: 10.1038/jp.2014.130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]